Develops drugs for liver diseases.
Dec 2025Revenue $41.0K/yrExpenses $94.5M/yr
No trendCash runway ≈ 4.3 years from Jun 2026
Figures by year
When will Altimmune be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $41.0K and expenses $94.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $41.0K | $94.5M | −$94.5M |
| Dec 2024 | $20.0K | $103M | −$103M |
| Dec 2023 | $426K | $96.4M | −$95.9M |
| Dec 2022 | −$68.0K | $87.7M | −$87.7M |
| Dec 2021 | $4.41M | $101M | −$96.9M |
| Dec 2020 | $8.19M | $63.0M | −$54.8M |
| Dec 2019 | $5.80M | $27.3M | −$21.5M |
| Dec 2018 | $10.3M | $53.2M | −$42.8M |
| Dec 2017 | $10.7M | $62.8M | −$52.0M |
| Dec 2016 | $3.24M | $14.3M | −$11.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.